January 26, 2015 3:35 AM ET


Company Overview of Danube Pharmaceuticals, Inc.

Company Overview

Danube Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the research and development of drugs and technologies for the treatment of ophthalmic and other related diseases. Its DNB-001 is a small molecule for the treatment of glaucoma. The company also engages in the research of efficacy of novel oral therapy with a dual mechanism of action, in lowering the intraocular pressure ("IOP") in patients with ocular hypertension. The company was incorporated in 2005 and is based in New York, New York.

689 Fifth Avenue

14th Floor

New York, NY 10022

United States

Founded in 2005





Key Executives for Danube Pharmaceuticals, Inc.

Chief Executive Officer
Chief Operating Officer
Age: 63
Senior Director of Clinical Operations
Compensation as of Fiscal Year 2014.

Similar Private Companies By Industry

Company Name Region
Akceli Inc. United States
Propagenix Inc. United States
MicroDiagnosis Inc. United States
Ventria Bioscience, Inc. United States
Algenetix, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Danube Pharmaceuticals, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.